Abstract:Recent evolution in drug repurposing has brought new anticipation, especially in the conflict against neurodegenerative diseases (NDDs). The traditional approach to developing novel drugs for these complex disorders is laborious, time-consuming, and often abortive. However, drug reprofiling which is the implementation of illuminating novel therapeutic applications of existing approved drugs, has shown potential as a promising strategy to accelerate the hunt for therapeutics. The advancement of computational approaches and artificial intelligence has expedited drug repurposing. These progressive technologies have enabled scientists to analyse extensive datasets and predict potential drug-disease interactions. By prospecting into the existing pharmacological knowledge, scientists can recognise potential therapeutic candidates for reprofiling, saving precious time and resources. Preclinical models have also played a pivotal role in this field, confirming the effectiveness and mechanisms of action of repurposed drugs. Several studies have occurred in recent years, including the discovery of available drugs that demonstrate significant protective effects in NDDs, relieve debilitating symptoms, or slow down the progression of the disease. These findings highlight the potential of repurposed drugs to change the landscape of NDD treatment. Here, we present an overview of recent developments and major advances in drug repurposing intending to provide an in-depth analysis of traditional drug discovery and the strategies, approaches and technologies that have contributed to drug repositioning. In addition, this chapter attempts to highlight successful case studies of drug repositioning in various therapeutic areas related to NDDs and explore the clinical trials, challenges and limitations faced by researchers in the field. Finally, the importance of drug repositioning in drug discovery and development and its potential to address discontented medical needs is also highlighted.

Drug repurposing for rare: progress and opportunities for the rare disease community

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Drug Repurposing: A Leading Strategy for New Threats and Targets

Artificial intelligence in drug repurposing for rare diseases: a mini-review

Drug repositioning for orphan diseases.

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

Drug repurposing: progress, challenges and recommendations

How drug repurposing can advance drug discovery: challenges and opportunities

Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences

Drug Repurposing: Far Beyond New Targets for Old Drugs

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

International Drug Repurposing Patent Landscaping, Part 1: Rare Diseases 2010–2023

Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government

Reimagining old drugs with new tricks: Mechanisms, strategies and notable success stories in drug repurposing for neurological diseases

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

Drug repurposing: a systematic review on root causes, barriers and facilitators

Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing

Pharmaceutical policy and innovation for rare diseases: A narrative review

New clinical insight in amyotrophic lateral sclerosis and innovative clinical development from the non-profit repurposing trial of the old drug guanabenz